Clinical Trials | March 07, 2026
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The company announced positive topline data from the Phase II ZUPREME-1 trial
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Subscribe To Our Newsletter & Stay Updated
